Sugi Predict

Sugi Predict / Compounds / SCHEMBL330227

SCHEMBL330227

SCHEMBL330227

Nc1nc(-c2ccccc2)c(-c2ccccc2)o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 11/20 1.00
▸ FBP1 P09467 1/20 0.56
▸ MAPK13 O15264 1/20 0.56
▸ MAPK12 P53778 1/20 0.56
▸ MAPK11 Q15759 1/20 0.56
▸ MAPK14 Q16539 1/20 0.56
▸ CYP2C19 P33261 2/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ NR4A1 P22736 3/20 0.50
▸ NR4A3 Q92570 3/20 0.50
▸ GAA P10253 1/20 0.47
▸ KDM4E B2RXH2 5/20 0.47
▸ RXRA P19793 5/20 0.47
▸ RXRB P28702 5/20 0.47
▸ LMNA P02545 3/20 0.47
▸ RXRG P48443 3/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ HPGD P15428 2/20 0.47
▸ TSHR P16473 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5154427 0.81 NR4A2 (0.68) NR4A2FBP1MAPK13MAPK12MAPK11
SCHEMBL5184570 0.81 NR4A2 (0.65) NR4A2FBP1MAPK13MAPK12MAPK11
SCHEMBL25351821 0.80 NR4A2 (0.67) NR4A2FBP1MAPK13MAPK12MAPK11
SCHEMBL5318103 0.78 NR4A2 (0.63) NR4A2FBP1MAPK13MAPK12MAPK11
SCHEMBL5154448 0.78 NR4A2 (0.63) NR4A2FBP1CYP2C19CYP1A2KDM4E
SCHEMBL762311 0.77 NR4A2 (0.62) NR4A2MAPK13MAPK12MAPK11MAPK14
SCHEMBL14448837 0.76 HSD17B10 (0.66) NR4A2MAPK13MAPK12MAPK11MAPK14
SCHEMBL2091239 0.75 MAPK13 (0.83) NR4A2MAPK13MAPK12MAPK11MAPK14
SCHEMBL2091238 0.75 NR4A2 (0.60) NR4A2MAPK13MAPK12MAPK11MAPK14
SCHEMBL11450560 0.75 NR4A2 (0.65) NR4A2MAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 — — EP disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 — — WO disclosed
US-8703761-B2 Organic compounds NOVARTIS AG (CH) 2014-04-22 — — US disclosed
EP-2559455-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2013-02-20 — — EP disclosed
EP-2548618-A2 Organic compounds Novartis AG (CH) 2013-01-23 — — EP disclosed
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 — — US disclosed
CN-101849953-B Inflammatory cytokine release inhibitor INST MED MOLECULAR DESIGN INC 2012-04-25 — — CN disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 — — US disclosed
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2010-10-28 — — US disclosed
CN-101849953-A Inflammatory cytokine release inhibitor INST MED MOLECULAR DESIGN INC 2010-10-06 — — CN disclosed
EP-1510207-A1 THERAPEUTIC DRUG FOR DIABETES Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 — — EP disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 — — US disclosed
CN-1489458-A Inflammatory cytokine production dissociation inhibitor ��ʽ����ҽҩ��������о��� 2004-04-14 — — CN disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 — — EP disclosed
US-6057318-A ANTAGONISTS OF PLATELET ACTIVATING FACTOR ACETHER SANOFI (FR) 2000-05-02 — — US disclosed
US-5891894-A 2-AMINO OXAZOLE DERIVATIVES; ANTAGONISTS OF PLATELET ACTIVATING FACTOR USEFUL IN TREATMENT OF ASTHMA, INFLAMMATION, CARDIOVASCULAR DISORDERS, RENAL DISEASES, OR AS CONTRACEPTIVES SANOFI (FR) 1999-04-06 — — US disclosed
US-5891893-A 5-AMINO-1,2,4-OXA(OR THIA)DIAZOLES; ANTAGONISTS OF PLATELET ACTIVATING FACTOR USEFUL IN TREATMENT OF ASTHMA, ALLERGIES, INFLAMMATION, CARDIOVASCULAR DISEASES, RENAL DISEASES, OR AS CONTRACEPTIVES SANOFI (FR) 1999-04-06 — — US disclosed
US-5780468-A ANTAGONIST OF PLATELET ACTIVATING FACTOR SANOFI (FR) 1998-07-14 — — US disclosed
US-5470855-A Anticoagulants SANOFI (FR) 1995-11-28 — — US disclosed
US-4242495-A COATINGS, MOLDINGS, FOAMS THE FIRESTONE TIRE & RUBBER COMPANY (US) 1980-12-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A NR4A2 1143/4885FBP1 2161/4885MAPK13 952/4885
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB NR4A2 569/4885FBP1 2002/4885MAPK13 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.